13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $190000 | -$74M | 0.0% | -40856.3% | -109.8% | -79.7% | -$62M | — | $11M |
| 2024 | $235000 | -$64M | 0.0% | -28899.6% | -91.4% | -66.1% | -$69M | — | $11M |
| 2023 | $353000 | -$50M | 0.0% | -15557.8% | -55.6% | -41.8% | -$37M | — | $23M |
| 2022 | $10M | -$45M | 0.0% | -446.8% | -63.4% | -47.3% | -$44M | — | $10M |
| 2021 | $0 | -$34M | — | — | -30.9% | -29.2% | -$33M | — | $2M |
| 2020 | $10M | -$16M | 0.0% | -152.2% | -51.3% | -41.9% | -$16M | — | $17M |
| 2019 | $422000 | -$16M | 0.0% | -5445.0% | -76.6% | -44.8% | -$20M | — | $9M |
| 2018 | — | -$35M | — | — | -102.6% | -65.4% | -$32M | $16M | $23M |
| 2017 | — | -$48M | — | — | -75.0% | -53.9% | -$44M | $20M | $21M |
| 2016 | — | -$58M | — | — | -92.1% | -71.8% | -$53M | $10M | $38M |
| 2015 | — | -$48M | — | — | -41.7% | -37.0% | — | $5M | $53M |
| 2014 | — | -$24M | — | — | 26.8% | -118.0% | — | — | $14M |
| 2013 | — | -$20M | — | — | 30.3% | — | — | — | $36M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$10M | — | — | -21.1% | -14.8% | -$9M | — | $16M |
| Mar '26 | — | -$11M | — | — | -18.6% | -13.5% | -$13M | — | $10M |
| Dec '25 | $0 | -$14M | — | — | -20.7% | -15.0% | -$12M | — | $11M |
| Sep '25 | $190000 | -$26M | 0.0% | -14076.3% | -32.1% | -24.1% | -$21M | — | $6M |
| Jun '25 | $0 | -$20M | — | — | -26.1% | -19.2% | -$14M | — | $17M |
| Mar '25 | $0 | -$15M | — | — | -19.8% | -15.3% | -$15M | — | $10M |
| Dec '24 | $0 | -$15M | — | — | -21.4% | -15.5% | -$13M | — | $11M |
| Sep '24 | $0 | -$17M | — | — | -26.4% | -18.8% | -$13M | — | $11M |
| Jun '24 | $0 | -$16M | — | — | -20.0% | -15.4% | -$20M | — | $7M |
| Mar '24 | $235000 | -$15M | 0.0% | -7079.1% | -18.3% | -13.7% | -$22M | — | $7M |
| Dec '23 | $0 | -$15M | — | — | -16.3% | -12.2% | -$11M | — | $23M |
| Sep '23 | $353000 | -$11M | 0.0% | -3573.7% | -11.5% | -9.1% | -$10M | — | $10M |
| Jun '23 | $0 | -$12M | — | — | -11.6% | -9.3% | -$14M | — | $12M |
| Mar '23 | $0 | -$12M | — | — | -10.9% | -8.7% | -$2M | — | $21M |
| Dec '22 | $10M | -$8M | 0.0% | -76.5% | -10.5% | -7.9% | -$11M | — | $10M |
| Sep '22 | $0 | -$13M | — | — | -17.2% | -13.8% | -$13M | — | $18M |
| Jun '22 | — | -$12M | — | — | -14.3% | -12.9% | -$9M | — | $8M |
| Mar '22 | — | -$12M | — | — | -12.3% | -11.6% | -$10M | — | $8M |
| Dec '21 | — | -$9M | — | — | -7.8% | -7.4% | -$8M | — | $2M |
| Sep '21 | — | -$8M | — | — | -6.5% | -6.2% | -$12M | — | $60M |
How the market has priced ATYR against its own fundamentals since 2024-06 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, aTYR PHARMA INC's revenue has declined 55.1% per year. These are computed facts, not advice.
As of FY2025, aTYR PHARMA INC reported — of total debt against $11M of cash.
In FY2025, gross margin was —, operating margin -40856.3%, and net margin -39009.5%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.